Our Research & Development

Our process to investigate for new medicines

Our research focuses on science related to the neurobiology and neurophysiology of neurodegenerative processes. We implement state of the art technologies, such as reverse genomics, advanced imaging, human disease specific transgenic animals, neural stem cell biology.

The development of a new medicine is a long lasting and tedious process, and takes more than 10 years to translate the initial idea and working hypothesis in the laboratory to the bed of patients and to safe and efficacious clinical use.

Our goal is to develop new medicines for human neurodegenerative diseases, such as Alzheimer’s or Parkinson’s diseases, Multiple Sclerosis or degeneration of the neurons in Retina in the eyes of patients with diabetes or during aging.

Developing a multidynamic approach to halt and treat neurodegenerative diseases

Neurodegenerative diseases are complex conditions, involving multiple genes and cellular pathways. They are characterised by the loss of neurons of different types (depending upon the disease) through cell apoptosis or autophagy, and the induction of destructive brain inflammation mediated by the activation of glia. In parallel, the degenerating neural tissues lose their capacity to generate fresh neurons and replace the damaged ones with activation of neural stem cells and de novo neurogenesis. Most attempts to develop therapeutics of neurodegenerative diseases target one of these deleterious conditions while the others continue their neuro-damaging actions.

Our therapeutic approach is to simultaneously target all these three phenomena (apoptosis of neurons, neuro-inflammation and neurogenesis) developing non-toxic, brain permeable, multifaceted small molecules with anti-apoptotic-neuroprotective, anti-neuroinflamnatory and neurogenic properties in one molecule.

Developing and investigating compounds that can alter the processes of neurodegenerative diseases

Our key therapeutic targets are Neurotrophins and their cellular receptors. Polypeptide neurotrophins control the survival of neurons, the proliferation of neural stem cells and the formation of fresh, normal neurons, and the activation of glial cells and brain inflammation.

Using in silico molecular dynamics, artificial intelligence techniques we design and synthesise small molecules, activators of neurotrophin receptors, mimetics of endogenous neurotrophins.

Our chemists synthesize a large chemical library of our compounds, then we narrow down the number of compounds by further testing, to focus on lead compounds, precursors to our ultimate drug. We finish by optimising the lead compounds with chemistry to ensure the desired pharmacodynamic and pharmacokinetic properties. We focus on compounds that:

  • specifically bind with high affinity to the appropriate for the disease neurotrophin receptor
  • are efficiently and safely absorbed by the body and reach the brain
  • remain in the brain long enough to act effectively
  • are efficiently manufactured to produce a stable drug for clinical use
  • are non-toxic with few side effects

Delineate how a compound works in a specific neurodegenerative condition

Our researchers collaborate with world-class scientists in the field of neurodegeneration to test our lead compounds in neuronal cell cultures and tissues and in specific for the disease transgenic animal models. We thus define the exact mechanism of action of our compounds and validate their proof of concept in animals simulating the specific human neurodegenerative disease. When this work has been successful done, our scientists consider a compound testing it in humans.

The minds behind the medicine

Our scientists are unlocking the secrets of the brain and are trying to find treatments for the most challenging neurodegenerative conditions. World class science needs world class scientists to collaborate with passion and purpose. BioNature’s international preeminent team is comprised of respected innovators with a dedication and commitment to advance the field.

Scientific Partners